← All trials
NCT04723524
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 22, 2020
- Primary completion
- Aug 23, 2021
- Completion date
- Aug 23, 2021
- First posted
- Jan 25, 2021
- Last posted
- Oct 6, 2021
- Enrollment
- 402
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of KarachiLead sponsor
- University of KarachiReponsible party - principal investigator
- University of KarachiOverall official - principal investigator
- Indus HospitalCollaborator
- Dr. Ruth K.M. Pfau Civil Hospital, KarachiCollaborator
- Dow University of Health SciencesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.